Holen Sie sich die Stockscreener-App
9.59
1.80%
0.17
Handel nachbörslich:
9.58
-0.010
-0.10%
Schlusskurs vom Vortag:
$9.42
Offen:
$9.46
24-Stunden-Volumen:
1.45M
Relative Volume:
0.20
Marktkapitalisierung:
$1.11B
Einnahmen:
$52.86M
Nettoeinkommen (Verlust:
$-480.19M
KGV:
-2.0448
EPS:
-4.6899
Netto-Cashflow:
$-421.82M
1W Leistung:
+9.10%
1M Leistung:
+14.85%
6M Leistung:
+0.21%
1J Leistung:
-20.41%
1-Tages-Spanne:
$9.26
$9.62
1-Wochen-Bereich:
$8.74
$9.85
52-Wochen-Spanne:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.59 | 1.09B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Is Intellia Therapeutics Inc 38I a good long term investmentExit Strategy Tips & Download Our Free Trading Blueprint - earlytimes.in
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteTrade Ideas & Long-Term Growth Plans - ulpravda.ru
Will Intellia Therapeutics Inc. stock continue dividend increasesJuly 2025 Momentum & Stepwise Trade Signal Implementation - DonanımHaber
Will Intellia Therapeutics Inc. (38I) stock hit analyst forecastsJuly 2025 Retail & Weekly High Momentum Picks - DonanımHaber
Is Intellia Therapeutics Inc. stock a top momentum play2025 Stock Rankings & Accurate Buy Signal Alerts - DonanımHaber
Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - Улправда
Intellia Therapeutics (NTLA) Receives a Buy from Leerink Partners - The Globe and Mail
623,600 Shares in Intellia Therapeutics, Inc. $NTLA Acquired by Marex Group plc - MarketBeat
Intellia Therapeutics, Inc. $NTLA Shares Sold by Nikko Asset Management Americas Inc. - MarketBeat
Intellia Therapeutics CEO Sells Shares Under Trading Plan - TradingView — Track All Markets
Intellia Therapeutics, Inc. $NTLA Shares Purchased by Armistice Capital LLC - MarketBeat
(NTLA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
JPMorgan Chase & Co. Purchases 396,858 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Volume Recap: Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Free Weekly Watchlist of Top Performers - moha.gov.vn
Intellia Therapeutics (NASDAQ:NTLA) Nasdaq Index Expands Genetic Research - Kalkine Media
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Why Intellia Therapeutics (NTLA) Is Up 6.9% After Disclosing Serious Liver Safety Events In Lead CRISPR Trials - Sahm
Would You Still Hold Intellia Therapeutics Stock If It Fell Another 30%? - Trefis
Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky About Pending Class ActionNTLA - 28/22 News
Schroder Investment Management Group Increases Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Focuses on Pipeline Development Amid Stiff Competition - MSN
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Will Intellia Therapeutics Inc. (38I) stock benefit from mergersJuly 2025 Momentum & Weekly Stock Performance Updates - Newser
How analysts revise price targets for Intellia Therapeutics Inc. (38I) stockWeekly Risk Report & Accurate Technical Buy Alerts - Newser
Intellia Therapeutics (NASDAQ: NTLA) issues 12,600 inducement RSUs to three new employees - Stock Titan
Will Intellia Therapeutics Inc. (38I) stock recover faster than industryMarket Volume Summary & Technical Pattern Alert System - Newser
What dividend safety rating applies to Intellia Therapeutics Inc. (38I) stockMarket Sentiment Report & AI Based Trade Execution Alerts - Newser
Why analysts maintain buy rating on Intellia Therapeutics Inc. (38I) stockJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - Newser
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory - Finviz
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.1%Should You Buy? - MarketBeat
Does Intellia Therapeutics Inc. (38I) stock trade below intrinsic valueQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - Newser
Is Intellia Therapeutics Inc. stock attractive for growth ETFs2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
Why Intellia Therapeutics Inc. (38I) stock remains top ratedWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
What is the fair value estimate for Intellia Therapeutics Inc. (38I) stock in 2025Trend Reversal & Accurate Entry/Exit Alerts - Newser
Will Intellia Therapeutics Inc. (38I) stock outperform value peersJuly 2025 Summary & Technical Pattern Based Buy Signals - Newser
Will Intellia Therapeutics Inc. (38I) stock profit from AI boomMarket Activity Summary & Capital Protection Trade Alerts - Newser
Intellia Therapeutics: Critical Safety Updates Are ImminentExpect Volatility (NTLA) - Seeking Alpha
Is Intellia Therapeutics Inc. (38I) stock nearing a technical breakout2025 Price Targets & Weekly High Momentum Picks - Newser
Can Intellia Therapeutics Inc. (38I) stock survive global slowdown - Newser
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble - MSN
Intellia Therapeutics (NASDAQ:NTLA) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Geode Capital Management LLC Boosts Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Can Intellia Therapeutics (NTLA) Rebuild Trust Amid Safety Setbacks and Regulatory Challenges? - Sahm
How (NTLA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade - Yahoo Finance
Intellia Therapeutics, Inc. $NTLA Shares Sold by Orchard Capital Management LLC - MarketBeat
Pullback Watch: Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Weekly Recap & Intraday High Probability Alerts - moha.gov.vn
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):